What Now, What Next? Appropriate Management for mUC
How I Practice Video #2: Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC
Pre-assessment

Before you view this activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. What are your specialty & credentials?

Medical Oncologist (MD/DO)

Surgical Oncologist (MD/DO)

Radiologist (MD/DO)

Hematologist/Oncologist (MD/DO)

Other MD/DO

Trainee/Fellow

Nurse

Pharmacist

Other (please specify)

Question Title

* 2. What is your community of practice?

Academic

Community

Other (please specify)

Question Title

* 3. Per NCCN guidelines, which of the following is a preferred first-line regimen for cisplatin eligible patients with mUC?

Atezolizumab

Gemcitabine and carboplatin

Nivolumab, gemcitabine, and cisplatin

Pembro + EV

Question Title

* 4. Erdafitinib is recommended as a second-line treatment option for patients with which genetic alteration?

ARID1A

FGFR3

KDM6A

TP53

Question Title

* 5. 75yo woman with newly diagnosed PD-L1 positive mUC has a GFR of 25mL/min. According to the EAU guidelines, which of the following would be an appropriate 1L treatment option for her?

Atezo or Pembro

Gemcitabine

Nivolumab

Pembro + EV

Question Title

* 6. A 77-year-old man with mUC and no identifiable genetic alterations receives 1L EV+P and 2L gem + cis. He presents 9 months after completing 2L treatment with progressive disease. Which of the following would be an appropriate 3L treatment for him based on NCCN guidelines?

Atezolizumab

Nivolumab

Pembrolizumab

Sacituzumab govitecan

Question Title

* 7. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity).

Completing the fields below does not immediately qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

*Please note that we will not forward or sell your contact information.

First & Last Name

State/Province

ZIP/Postal Code

Country

Email Address

What Now, What Next? Appropriate Management for mUCHow I Practice Video #2: Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC*Pre-assessment*

Question Title

* 1. What are your specialty & credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. Per NCCN guidelines, which of the following is a preferred first-line regimen for cisplatin eligible patients with mUC?

Question Title

* 4. Erdafitinib is recommended as a second-line treatment option for patients with which genetic alteration?

Question Title

* 5. 75yo woman with newly diagnosed PD-L1 positive mUC has a GFR of 25mL/min. According to the EAU guidelines, which of the following would be an appropriate 1L treatment option for her?

Question Title

* 6. A 77-year-old man with mUC and no identifiable genetic alterations receives 1L EV+P and 2L gem + cis. He presents 9 months after completing 2L treatment with progressive disease. Which of the following would be an appropriate 3L treatment for him based on NCCN guidelines?

Question Title

What Now, What Next? Appropriate Management for mUC
How I Practice Video #2: Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC
Pre-assessment